寡转移性去势敏感性前列腺癌中转移灶导向治疗联合或不联合雄激素剥夺治疗的多机构分析
这项多中心、国际回顾性队列纳入263例经传统影像定义的寡转移性去势敏感性前列腺癌患者,105例接受转移灶导向治疗(MDT)联合雄激素剥夺治疗(ADT),158例接受MDT单用。联合ADT与更好的5年生化、远处及复合无进展生存相关,约10%患者单用MDT获得持久控制。
要点
- MDT联合ADT组5年生化无进展生存为24%,MDT单用组为11%(HR 0.48,95%CI 0.36-0.64)。
- MDT联合ADT组5年远处无进展生存为41%,MDT单用组为29%(HR 0.56,95%CI 0.40-0.78)。
- MDT联合ADT组5年复合无进展生存为19%,MDT单用组为9%(HR 0.50,95%CI 0.38-0.67)。
核心结论
- 在这项大型多机构报告中,MDT同时联合ADT似乎改善至前列腺特异性抗原进展和远处复发的时间,同时注意到约10%患者单用MDT获得持久控制。
- 正在进行的3期研究将有助于进一步明确omCSPC的治疗选择。
研究设计与样本
- 多中心、国际回顾性队列,纳入经传统影像定义的寡转移性去势敏感性前列腺癌患者,共263例,其中105例接受MDT联合ADT,158例接受MDT单用。
主要发现
- 大多数患者为异时性疾病(90.5%)。
- 5年生化无进展生存:MDT联合ADT组24% vs MDT单用组11%(HR 0.48,95%CI 0.36-0.64)。
- 5年远处无进展生存:MDT联合ADT组41% vs MDT单用组29%(HR 0.56,95%CI 0.40-0.78)。
- 5年复合无进展生存:MDT联合ADT组19% vs MDT单用组9%(HR 0.50,95%CI 0.38-0.67)。
- 多因素分析校正治疗前变量后,使用ADT与改善的生化无进展生存(HR 0.43,p < 0.001)、远处无进展生存(HR 0.45,p = 0.002)和复合无进展生存(HR 0.44,p < 0.001)相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metastasis-directed therapy (MDT) is increasingly being used in oligometastatic castration-sensitive prostate cancer (omCSPC). However, it is currently unclear how to optimally integrate MDT with the standard of care of systemic hormonal therapy. OBJECTIVE: To report long-term outcomes of MDT alone versus MDT and a defined course of androgen deprivation therapy (ADT) in omCSPC. DESIGN, SETTING, AND PARTICIPANTS: Here, a multicenter, international retrospective cohort of omCSPC as defined by conventional imaging was reported. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Biochemical progression-free survival (bPFS), distant progression-free survival (dPFS), and combined biochemical or distant progression-free survival (cPFS) were evaluated with Kaplan-Meier and multivariable Cox proportional hazard regression models. RESULTS AND LIMITATIONS: A total of 263 patients were included, 105 with MDT + ADT and 158 with MDT alone. The majority of patients had metachronous disease (90.5%). Five-year bPFS, dPFS, and cPFS were, respectively, 24%, 41%, and 19% in patients treated with MDT + ADT and 11% (hazard ratio [HR] 0.48, 95% confidence interval [CI] 0.36-0.64), 29% (HR 0.56, 95% CI 0.40-0.78), and 9% (HR 0.50, 95% CI 0.38-0.67) in patients treated with MDT alone. On a multivariable analysis adjusting for pretreatment variables, the use of ADT was associated with improved bPFS (HR 0.43, p < 0.001), dPFS (HR 0.45, p = 0.002), and cPFS (HR 0.44, p < 0.001). CONCLUSIONS: In this large multi-institutional report, the addition of concurrent ADT to MDT appears to improve time to prostate-specific antigen progression and distant recurrence, noting that about 10% patients had durable control with MDT alone. Ongoing phase 3 studies will help further define treatment options for omCSPC. PATIENT SUMMARY: Here, we report a large retrospective review evaluating the outcomes of metastasis-directed therapy with or without a limited course of androgen deprivation for patients with oligometastatic castration-sensitive prostate cancer. This international multi-institutional review demonstrates that the addition of androgen deprivation therapy to metastasis-directed therapy (MDT) improves progression-free survival. While a proportion of patients appear to have long-term disease control with MDT alone, further work in biomarker discovery is required to better identify which patients would be appropriate for de-escalated therapy.
引用
- Deek MP, Sutera P, Jing Y, et al. Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer. Eur Urol Oncol. 2024. PMID: 38570239. doi:10.1016/j.euo.2024.03.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。